117 related articles for article (PubMed ID: 38311851)
1. DLK1/DIO3 locus upregulation by a β-catenin-dependent enhancer drives cell proliferation and liver tumorigenesis.
Sanceau J; Poupel L; Joubel C; Lagoutte I; Caruso S; Pinto S; Desbois-Mouthon C; Godard C; Hamimi A; Montmory E; Dulary C; Chantalat S; Roehrig A; Muret K; Saint-Pierre B; Deleuze JF; Mouillet-Richard S; Forné T; Grosset CF; Zucman-Rossi J; Colnot S; Gougelet A
Mol Ther; 2024 Apr; 32(4):1125-1143. PubMed ID: 38311851
[TBL] [Abstract][Full Text] [Related]
2. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
3. Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
Loesch R; Caruso S; Paradis V; Godard C; Gougelet A; Renault G; Picard S; Tanaka I; Renoux-Martin Y; Perret C; Taketo MM; Zucman-Rossi J; Colnot S
J Hepatol; 2022 Aug; 77(2):424-435. PubMed ID: 35257829
[TBL] [Abstract][Full Text] [Related]
4. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
[TBL] [Abstract][Full Text] [Related]
5. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
7. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
[TBL] [Abstract][Full Text] [Related]
8. DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival.
Luk JM; Burchard J; Zhang C; Liu AM; Wong KF; Shek FH; Lee NP; Fan ST; Poon RT; Ivanovska I; Philippar U; Cleary MA; Buser CA; Shaw PM; Lee CN; Tenen DG; Dai H; Mao M
J Biol Chem; 2011 Sep; 286(35):30706-30713. PubMed ID: 21737452
[TBL] [Abstract][Full Text] [Related]
9. Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for liver tumor promotion.
Lempiäinen H; Couttet P; Bolognani F; Müller A; Dubost V; Luisier R; Del Rio Espinola A; Vitry V; Unterberger EB; Thomson JP; Treindl F; Metzger U; Wrzodek C; Hahne F; Zollinger T; Brasa S; Kalteis M; Marcellin M; Giudicelli F; Braeuning A; Morawiec L; Zamurovic N; Längle U; Scheer N; Schübeler D; Goodman J; Chibout SD; Marlowe J; Theil D; Heard DJ; Grenet O; Zell A; Templin MF; Meehan RR; Wolf RC; Elcombe CR; Schwarz M; Moulin P; Terranova R; Moggs JG
Toxicol Sci; 2013 Feb; 131(2):375-86. PubMed ID: 23091169
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
12. A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer.
Rappaport JA; Entezari AA; Caspi A; Caksa S; Jhaveri AV; Stanek TJ; Ertel A; Kupper J; Fortina PM; McMahon SB; Jaynes JB; Snook AE; Waldman SA
Cell Mol Gastroenterol Hepatol; 2022; 13(4):1276-1296. PubMed ID: 34954189
[TBL] [Abstract][Full Text] [Related]
13. Male-specific coordinated changes in expression of miRNA genes, but not other genes within the DLK1-DIO3 locus in multiple sclerosis.
Baulina N; Kiselev I; Kozin M; Kabaeva A; Boyko A; Favorova O
Gene; 2022 Aug; 836():146676. PubMed ID: 35714798
[TBL] [Abstract][Full Text] [Related]
14. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
15. Upregulated YAP promotes oncogenic CTNNB1 expression contributing to molecular pathology of hepatoblastoma.
Lu S; Jiang M; Chen Q; Luo X; Cao Z; Huang H; Zheng M; Du J
Pediatr Blood Cancer; 2022 Sep; 69(9):e29705. PubMed ID: 35404538
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-298 represses hepatocellular carcinoma progression by inhibiting CTNND1-mediated Wnt/β-catenin signaling.
Cao N; Mu L; Yang W; Liu L; Liang L; Zhang H
Biomed Pharmacother; 2018 Oct; 106():483-490. PubMed ID: 29990836
[TBL] [Abstract][Full Text] [Related]
17. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
Liang Y; Feng Y; Zong M; Wei XF; Lee J; Feng Y; Li H; Yang GS; Wu ZJ; Fu XD; Feng GS
Hepatology; 2018 May; 67(5):1807-1822. PubMed ID: 29152756
[TBL] [Abstract][Full Text] [Related]
18. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
19. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
[TBL] [Abstract][Full Text] [Related]
20. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
Senni N; Savall M; Cabrerizo Granados D; Alves-Guerra MC; Sartor C; Lagoutte I; Gougelet A; Terris B; Gilgenkrantz H; Perret C; Colnot S; Bossard P
Gut; 2019 Feb; 68(2):322-334. PubMed ID: 29650531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
